An open-label randomised phase 2 trial shown that 177Lu-PSMA-617 compared with cabazitaxel (a semi synthetic taxane with poor affinity for P-gp) in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events (65). Here, FOLH1 is linked to prostate carcinoma.